Compare Fortinet Inc (FTNT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs Neurocrine Biosciences Inc — how do they compare? Fortinet Inc trades at $192.77 (market cap $138.75B), while Neurocrine Biosciences Inc trades at $142.45 (market cap $14.36B). The key difference: Fortinet Inc is far larger — about 9.7× Neurocrine Biosciences Inc's market cap, and Fortinet Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fortinet Inc for 72 Days and Neurocrine Biosciences Inc for 23 Days on average.
| FTNT | NBIX | |
|---|---|---|
Market Cap | $138.75B | $14.36B |
Volume | 2,956,908 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $191.27 | $185.50 |
52-Week Low | $75.23 | $123.10 |
Typical Hold Time | 72 Days | 23 Days |
Enterprise Value | $135.17B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTNT trades at $189.28, down 1.04% on the day but near its 52-week high, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $6.80B in 2025, supported by an 80.2% gross margin and robust cash flow from operations of $2.59B. Analyst sentiment is mixed, with 42% buy ratings but a consensus price target of $158.64 below the current price.
Outlook remains positive due to cybersecurity demand and AI-driven growth, but high valuation ratios (P/E of 66.82) pose risks. Competition and execution challenges could pressure margins. Institutional interest is strong, with recent position increases noted in SEC filings. The stock's momentum depends on continued earnings outperformance and market share gains in data center security.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
